Company news
Chugai Pharmaceutical Co., Ltd. (TSE:4519) news
Chugai Pharmaceutical Co., Ltd. news releases on 6ix. Latest, Sep 28, 2026: Notice Regarding Discontinuation of Development of GYM329 (emugrobart)…
Press releases & updates
Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA
September 28, 2026
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
September 9, 2026
Chugai and GSK Sign Exclusive License Agreement for Anti-Dengue Virus Antibody AID351
August 18, 2026
Chugai Announces 2026 2nd Quarter Results
July 27, 2026
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026)
July 24, 2026
F. Hoffmann-La Roche Announces Half Year Results 2026
July 23, 2026
Chugai Files New Drug Application in Japan for Sparsentan for the Treatment of IgA Nephropathy
June 22, 2026
Chugai Receives The Imperial Invention Prize, the Highest Honor of the FY2026 National Commendation for Invention, Recycling Antibody Technology Recognized for its Contribution to Pharmaceutical Research
May 26, 2026
Chugai Pharmaceutical : Alecensa Receives the World-First Tumor-Agnostic Approval for ALK Fusion Gene-Positive Solid Tumors Across Adult and Pediatric Patients
May 18, 2026
Chugai Pharmaceutical : Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Alecensa for ALK Fusion Gene-Positive Solid Tumors
May 18, 2026
Chugai Pharmaceutical : Q1 Results (Jan-Mar 2026)
April 24, 2026
Chugai Pharmaceutical : Announcement of Termination of Co-Promotion of Rituxan® in Japan (Anti-CD20 Monoclonal Antibody)
April 9, 2026
Mitsubishi Electric Announces Director Candidates
March 30, 2026
Chugai Pharmaceutical : Voting Results (Extraordinary Report) of the 115th Annual General Meeting of Shareholders
March 27, 2026
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
March 26, 2026
Chugai Pharmaceutical - Notice Regarding Discontinuation of Development of GYM329 in Spinal Muscular Atrophy and Facioscapulohumeral Muscular Dystrophy
March 24, 2026
Chugai Pharmaceutical : Obtains Regulatory Approval for Lunsumio and Polivy Combination Therapy for Additional Indication of Relapsed or Refractory Large B-cell Lymphoma
March 23, 2026
Chugai Pharmaceutical : Notice Regarding Discontinuation of Development of GYM329 (Emugrobart) in Spinal Muscular Atrophy (SMA) and Facioscapulohumeral Muscular Dystrophy (FSHD)
March 22, 2026
Chugai Pharmaceutical : Files for the Medical Device Component of the Port Delivery Platform with ranibizumab in Japan
March 19, 2026
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
February 24, 2026
Chugai Pharmaceutical : Launches “ELEVIDYS” as Japan’s First Regenerative Medical Product for Duchenne Muscular Dystrophy
February 19, 2026
Chugai Pharmaceutical : Anti-CD20 Monoclonal Antibody Rituxan® Approved for Treatment of Autoimmune Hemolytic Anemia
February 19, 2026
Chugai Pharmaceutical : NXT007 Suggests Favorable Tolerability and Efficacy in Phase I/II Study for Hemophilia A Following Direct Switch from Emicizumab without Washout Period
February 9, 2026
Chugai Pharmaceutical : Full Year Results (Jan-Dec 2025)
January 29, 2026
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
November 6, 2025
Renalys Pharma to be Acquired by Chugai Pharmaceutical
October 24, 2025
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
October 23, 2025
RANI: Chugai Deal Announced
October 20, 2025
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing
October 17, 2025
Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
August 26, 2025
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
August 7, 2025
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
August 7, 2025
Chugai Pharma Taiwan Honored at the AREA 2025 for its Social Empowerment and Green Innovation
August 3, 2025
Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases
July 7, 2025